Neurocrine Biosciences (NBIX) Cash & Current Investments (2010 - 2026)

Neurocrine Biosciences has reported Cash & Current Investments for 17 years, with the latest figure at $389.8 million in Q2 2026.

• Cash & Current Investments for Q2 2026 came in at $389.8 million, down 60.05% year-over-year; the trailing twelve-month figure through Jun 2026 was $389.8 million (down 60.05% YoY), and the FY2025 annual result was $1.5 billion, up 37.57% from the prior year.
• Cash & Current Investments fell to $389.8 million in Q2 2026, from $1.3 billion in the prior quarter.
• Over five years, Cash & Current Investments peaked at $1.5 billion in Q4 2025 and troughed at $389.8 million in Q2 2026.
• A 5-year average of $993.9 million and a median of $1.0 billion in 2022 frame the typical range for Cash & Current Investments.
• The widest annual swing landed in 2023, when Cash & Current Investments surged 50.66%; it then slumped 60.05% in 2026.
• A 5-year view of Cash & Current Investments shows it stood at $997.1 million in 2022, then climbed by 4.26% to $1.0 billion in 2023, then rose by 3.51% to $1.1 billion in 2024, then surged by 37.57% to $1.5 billion in 2025, then sank by 73.67% to $389.8 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $389.8 million in Q2 2026, $1.3 billion in Q1 2026, and $1.5 billion in Q4 2025.